Revvity, Inc.

As of October 31, 2025, Revvity, Inc. is considered very expensive and overvalued with a P/E ratio of 33, underperforming the S&P 500 significantly, as evidenced by its year-to-date return of -16.70% compared to the index's 16.30%.

As of October 31, 2025, Revvity, Inc. is considered overvalued with a valuation grade of very expensive, reflected by high financial metrics and underperformance against the S&P 500.

As of October 31, 2025, Revvity, Inc. is considered overvalued with a P/E ratio of 33 and has underperformed the S&P 500, raising concerns about its stock price relative to earnings growth prospects.

As of October 17, 2025, Revvity, Inc. is considered very expensive with a P/E ratio of 33 and has underperformed the S&P 500 with a year-to-date return of -16.30%.

As of October 17, 2025, Revvity, Inc. is considered very expensive and overvalued due to its high P/E ratio of 33 compared to peers, a PEG ratio of 3.05 indicating growth isn't justifying its price, and low returns on equity and capital, despite short-term outperformance against the S&P 500.

As of October 17, 2025, Revvity, Inc. is considered very expensive with a P/E ratio of 33 and has underperformed the S&P 500, indicating it may be overvalued compared to its peers.

As of October 3, 2025, Revvity, Inc. shows a mildly bearish trend with mixed technical signals, having outperformed the S&P 500 recently but underperformed year-to-date.

As of October 3, 2025, Revvity, Inc. shows a mildly bearish trend with mixed technical signals, underperforming the S&P 500 with year-to-date and one-year returns of -15.73% and -24.21%, respectively.

As of October 3, 2025, Revvity, Inc. shows a mildly bearish trend with mixed technical signals, underperforming the S&P 500 with a year-to-date return of -15.73% compared to the S&P's 14.18%.

As of September 2, 2025, Revvity, Inc. is in a bearish trend, indicated by negative signals from MACD, Bollinger Bands, moving averages, and KST, while significantly underperforming the S&P 500 with year-to-date and one-year returns of -21.37% and -29.56%, respectively.

As of August 22, 2025, Revvity, Inc. is considered very expensive and overvalued with a P/E ratio of 33, significantly underperforming the S&P 500 with a year-to-date return of -21.37% compared to the index's 12.22%.

As of June 18, 2025, Revvity, Inc. is considered overvalued with a valuation grade of expensive, reflected by a P/E ratio of 33 and an EV to EBITDA ratio of 15.29, which are higher than its peers, while the company has underperformed with a year-to-date decline of 14.93%.

As of June 17, 2025, the trend is mildly bearish, supported by daily moving averages and weekly indicators, despite some bullish signals from the MACD and RSI.

As of March 2022, the management team of Revvity, Inc. includes Mr. Alexandros Michas (Independent Non-Executive Chairman), Mr. Prahlad Singh (President and CEO), and several Independent Directors: Dr. Peter Barrett, Mr. Samuel Chapin, Dr. Sylvie Gregoire, and Mr. Michel Vounatsos. This team combines executive leadership with independent oversight for the company's governance and strategy.

Revvity, Inc. is a mid-cap provider of products and solutions in the Pharmaceuticals & Biotechnology industry, with recent net sales of $665 million and a net profit of $42 million. Key metrics include a P/E ratio of 33.00 and a market cap of approximately $11.1 billion.

As of Jun 18, Revvity, Inc. has a market capitalization of 11,098.61 million, with net sales of 2,769.86 million and a net profit of 296.05 million over the latest four quarters. The company reported shareholder's funds of 7,666.87 million and total assets of 12,392.48 million as of Dec 24.